Mar 29, 2019
CLS Therapeutics Announces Presentation on “Cancer Metabolism and Signalling” At The New York Academy Of Sciences

NEW YORK, March 29, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class Anc80-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Cancer Metabolism and Signaling” being held on May 9, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed Anc80) encoding DNase I of the treatment of pancreatic cancer animal model.

“These data in the animal model support our ongoing research program evaluating CLS-014 for the treatment of pancreatic cancer  and other malignancies associated with elevated cfDNA levels pointing out that patients with these cancers associated with extremely poor prognosis have a new hope,” stated G. Tetz, MD, PhD, co-founder and Chief Executive Officer.

Presentation Details

Title: “First-In-Class Anc80-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I”.

Summary: Background: In general, there is a balance between the level of serum cell-free DNA (cfDNA) and a plasma nuclease enzyme DNase I. Tumor progression is characterized by increased levels of circulating serum cfDNA that mainly originate from dead cancer cells and active release from both tumor cells and neutrophils. Increased levels of cfDNA are associated with tumor appearance and progression, mainly modulating TLR9 pathway or activating metastatic genes. The objective of this study is to evaluate the efficacy of AAV-based vector (in silico designed Anc80) encoding DNase I.

Methods: We used BxPC-3-luc orthotopic model of BALB/c nude mice, with or without nab-paclitaxel injected with Anc80 vector with hyperactive DNase I transgene cassette. The mice were monitored for bioluminescence, weekly. Tumor size and metastasis were assessed at the end of the study (day 30).

Results: Treatment of mice with vector encoding DNase I demonstrated significant decrease in tumor bioluminescence (by more than 53%) compared to untreated control (p < 0.05). The number of ovary, kidney, spleen, and liver metastatic cells were significantly lower in group treated DNase I vector.

Conclusion: The study, for the first time, showed a potential in the cancer therapeutic strategy employing a gene-therapy approach allowing long term expression of DNase I and destruction of cfDNA.

Aug 06, 2019

CLS Therapeutics Inc., an oncology focused gene therapy company, today announced that their project was selected as one of the 15 finalists to compete for the Boehringer Ingelheim Innovation Prize during the evening of August 15 at NYU Langone Health.

Mar 28, 2019

NEW YORK, March 28, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class Anc80-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Targeting Tumor Heterogeneity” being held on May 8, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed Anc80) encoding DNase I of the treatment of pancreatic cancer animal model.

Apr 01, 2019

NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class Anc80-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed Anc80) encoding DNase I of the treatment of pancreatic cancer animal model.